MEPIVACAINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Mepivacaine Hydrochloride patents expire, and when can generic versions of Mepivacaine Hydrochloride launch?
Mepivacaine Hydrochloride is a drug marketed by Belmora Llc, Hospira Inc, Intl Medication Sys, and Watson Labs. and is included in six NDAs.
The generic ingredient in MEPIVACAINE HYDROCHLORIDE is levonordefrin; mepivacaine hydrochloride. There are two drug master file entries for this compound. Additional details are available on the levonordefrin; mepivacaine hydrochloride profile page.
Summary for MEPIVACAINE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 4 |
NDAs: | 6 |
Raw Ingredient (Bulk) Api Vendors: | 112 |
Clinical Trials: | 79 |
Patent Applications: | 1,075 |
Formulation / Manufacturing: | see details |
DailyMed Link: | MEPIVACAINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for MEPIVACAINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
NorthShore University HealthSystem | Phase 4 |
Johnny K. Lee | Phase 4 |
Research Institute of Ophthalmology, Egypt | N/A |